Molecular Characteristics of Large Parathyroid Adenomas

被引:12
作者
Agarwal, Amit [1 ]
Pradhan, Roma [1 ]
Kumari, Niraj [2 ]
Krishnani, Narendra [2 ]
Shukla, Pooja [2 ]
Gupta, Sushil Kumar [3 ]
Chand, Gyan [1 ]
Mishra, A. [1 ]
Agarwal, Gaurav [1 ]
Verma, Ashok Kumar [1 ]
Mishra, Saroj Kanta [1 ]
机构
[1] Sanjay Gandhi Post Grad Inst Med Sci, Dept Endocrine Surg, Lucknow 226014, Uttar Pradesh, India
[2] Sanjay Gandhi Post Grad Inst Med Sci, Dept Pathol, Lucknow 226014, Uttar Pradesh, India
[3] Sanjay Gandhi Post Grad Inst Med Sci, Dept Endocrinol, Lucknow 226014, Uttar Pradesh, India
关键词
PRIMARY HYPERPARATHYROIDISM; CARCINOMA; PARAFIBROMIN; CANCER; DIAGNOSIS; PGP9.5; HRPT2; GENE; ABNORMALITIES; EXPRESSION;
D O I
10.1007/s00268-015-3380-2
中图分类号
R61 [外科手术学];
学科分类号
摘要
Introduction The clinical entity of large parathyroid adenomas (LPTAs) has not been well defined. It is speculated that LPTAs would have biochemical, histological, and molecular characteristics different from small adenomas. Our study aimed to find out occurrence of atypia and carcinomas in large parathyroid lesions and the presence of distinct molecular abnormalities in LPTAs. Materials and methods We divided the parathyroid lesions into large (>7 g, i.e., LPTAs) and small (<7 g) adenomas. We performed parafibromin, APC (adenomatous polyposis coli), galectin 3, and PGP9.5 (protein gene product 9.5) analysis by immunohistochemistry in adenomas without atypia, atypical adenomas, and carcinomas. Results Mean serum calcium, alkaline phosphatase, and intact PTH were significantly higher in large parathyroid tumor group. The presence of both atypical adenoma and carcinoma was higher in large parathyroid tumor group. There was higher percentage of atypia in patients with LPTAs >10 g (33 %), and 68 % of tumors showed at least one marker suggestive of malignancy in this group. Detailed analysis of immunohistochemical features of LPTA >10 g revealed that six patients showed complete loss of parafibromin immunoreactivity (out of these four showed atypia), while seven showed partial loss. In histopathologically proven malignancy (n = 9), six patients showed complete loss of parafibromin staining, 5 (55 %) APC negativity, and 45 % showed both galectin 3 and PGP9.5 positivity. Three out of these showed all IHC markers s/o malignancy, and all of them had evidence of metastases or recurrence. 32 % of atypical adenoma and 13 % of atypical adenoma showed complete loss of parafibromin staining, however none developed metastases or recurrence in follow-up (median follow-up 40 months). Loss of parafibromin staining (complete or partial) was higher in LPTA group (56 %) than that in small adenoma (39 %); however, it was not statistically significant. APC, galectin 3, and PGP9.5 markers suggestive were higher in LPTA group but were not significant. Conclusion LPTAs may show some morphological and immunohistochemical features suggestive of malignancy and can be considered a separate entity. However, the immunohistochemical markers are unable to clearly segregate those LPTAs that may show premalignant potential. Further, we would like to recommend that LPTAs showing complete parafibromin loss together with atypia should be kept under close follow-up.
引用
收藏
页码:607 / 614
页数:8
相关论文
共 31 条
[1]   Hyperparathyroidism and Malnutrition with Severe Vitamin D Deficiency [J].
Agarwal, Amit ;
Gupta, Sushil Kumar ;
Sukumar, Ranjith .
WORLD JOURNAL OF SURGERY, 2009, 33 (11) :2303-2313
[2]   Indian primary hyperparathyroidism patients with parathyroid carcinoma do not differ in clinicoinvestigative characteristics from those with benign parathyroid pathology [J].
Agarwal, G ;
Prasad, KK ;
Kar, DK ;
Krishnani, N ;
Pandey, R ;
Mishra, SK .
WORLD JOURNAL OF SURGERY, 2006, 30 (05) :732-742
[3]   Galectin-3 expression in parathyroid carcinoma: immunohistochemical study of 26 cases [J].
Bergero, N ;
De Pompa, R ;
Sacerdote, C ;
Gasparri, G ;
Volante, M ;
Bussolati, G ;
Papotti, M .
HUMAN PATHOLOGY, 2005, 36 (08) :908-914
[4]   Correlation of biochemical parameters with single parathyroid adenoma weight and volume [J].
Bindlish, V ;
Freeman, JL ;
Witterick, IJ ;
Asa, SL .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2002, 24 (11) :1000-1003
[5]   HISTOPATHOLOGICAL VARIABLES AND DNA CYTOMETRY IN PARATHYROID CARCINOMA [J].
BONDESON, L ;
SANDELIN, K ;
GRIMELIUS, L .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1993, 17 (08) :820-829
[6]   HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome [J].
Carpten, JD ;
Robbins, CM ;
Villablanca, A ;
Forsberg, L ;
Presciuttini, S ;
Bailey-Wilson, J ;
Simonds, WF ;
Gillanders, EM ;
Kennedy, AM ;
Chen, JD ;
Agarwal, SK ;
Sood, R ;
Jones, MP ;
Moses, TY ;
Haven, C ;
Petillo, D ;
Leotlela, PD ;
Harding, B ;
Cameron, D ;
Pannett, AA ;
Höög, A ;
Heath, H ;
James-Newton, LA ;
Robinson, B ;
Zarbo, RJ ;
Cavaco, BM ;
Wassif, W ;
Perrier, ND ;
Rosen, IB ;
Kristoffersson, U ;
Turnpenny, PD ;
Farnebo, LO ;
Besser, GM ;
Jackson, CE ;
Morreau, H ;
Trent, JM ;
Thakker, RV ;
Marx, SJ ;
Teh, BT ;
Larsson, C ;
Hobbs, MR .
NATURE GENETICS, 2002, 32 (04) :676-680
[7]   A reappraisal of the Rb1 gene abnormalities in the diagnosis of parathyroid cancer [J].
Cetani, F ;
Pardi, E ;
Viacava, P ;
Pollina, GD ;
Fanelli, G ;
Picone, A ;
Borsari, S ;
Gazzerro, E ;
Miccoli, P ;
Berti, P ;
Pinchera, A ;
Marcocci, C .
CLINICAL ENDOCRINOLOGY, 2004, 60 (01) :99-106
[8]   P53 ABNORMALITIES IN HUMAN PARATHYROID CARCINOMA [J].
CRYNS, VL ;
RUBIO, MP ;
THOR, AD ;
LOUIS, DN ;
ARNOLD, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 78 (06) :1320-1324
[9]   Parathyroid tumors and related disorders [J].
DeLellis, Ronald A. .
MODERN PATHOLOGY, 2011, 24 :S78-S93
[10]   Parathyroid carcinoma, atypical parathyroid adenoma, or parathyromatosis? [J].
Fernandez-Ranvier, Gustavo G. ;
Khanafshar, Elham ;
Jensen, Kristin ;
Zarnegar, Rasa ;
Lee, James ;
Kebebew, Electron ;
Duh, Quan-Yang ;
Clark, Orlo H. .
CANCER, 2007, 110 (02) :255-264